Vir Biotechnology, Inc. (VIR) Assets Fair Value Adjustment — Quarterly & Annual

Screener

Assets Fair Value Adjustment at other companies

Vir Biotechnology, Inc.VIR

$1.72M—

Peapack-Gladstone FinancialPGC

$8K-68.0%

Hancock Whitney CorporationHWC

-$5.04M—

LennarLEN

-$528.25K—

Western Alliance BancorporationWAL

-$3.1M-210%

Vir Biotechnology, Inc.VIR

$1.72M—

Other financials

Income statement

Revenue$238.9M+19,583%

Gross profit$238.9M+19,763%

Operating income$73.5M+162%

Net income$80.1M+172%

EPS (diluted)$0.47+159%

Balance sheet

Cash & equivalents$287.6M-6.1%

Total debt$93.3M-8.8%

Total equity$982.5M+3.7%

Total assets$1.2B+1.9%

Cash flow

Operating cash flow-$132.4M-69.5%

CapEx$32.0K-98.7%

Free cash flow-$132.8M-66.5%

Valuation

Market cap$1.48B+111%

Enterprise value$1.29B+159%

P/S4.9×-32.1×

Profitability

Gross margin96.1%-2.7pp

Operating margin-92.4%-45.5pp

Net margin-83%-40.9pp

FCF margin-686.5%-273pp

Returns & leverage

Return on equity-26.1%-7.9pp

Debt / equity0.1×0.0×

Current ratio6×-1.0×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AssetsFairValueAdjustment.

The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026. Open the filing →

Filed: Aug 5, 2026, 5:20 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001628280-26-053549

FAQ

What is Vir Biotechnology, Inc.'s assets fair value adjustment?: Vir Biotechnology, Inc. (VIR) reported assets fair value adjustment of $1.72M in Q2 2026.
What does assets fair value adjustment mean?: Assets Fair Value Adjustment as reported by Vir Biotechnology, Inc. Common Stock.

Ask your AI about Vir Biotechnology, Inc.'s assets fair value adjustment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk